Minims Cyclopentolate Chlorhydrate Bausch + Lomb Ireland Limited (Cyclopentolate Hydrochloride)

Cyclopentolate Hydrochloride, the active ingredient in Minims Cyclopentolate Chlorhydrate Bausch + Lomb Ireland Limited, is an anticholinergic (muscarinic antagonist) presented as eye drops for ocular use. It produces mydriasis and cycloplegia, facilitating pupil dilation and accommodation paralysis during eye examinations and refraction procedures in patients of all ages.

GNH USA supplies Minims Cyclopentolate Chlorhydrate Bausch + Lomb Ireland Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cyclopentolate Hydrochloride is used in ophthalmology to achieve controlled pupil dilation and temporary loss of accommodation. - Pupil dilation for ophthalmic examinations: provides reliable mydriasis to allow thorough retinal and optic nerve evaluation. - Cycloplegia for accurate refraction: temporarily paralyzes the ciliary muscle to enable precise measurement of refractive errors. - Adjunct in the management of anterior uveitis: helps reduce iris spasm and facilitates assessment of intra‑ocular inflammation.

Cyclopentolate eye drops may cause a range of ocular and systemic reactions.

Common Side Effects: - Stinging or burning sensation upon instillation - Transient blurred vision - Photophobia due to prolonged pupil dilation - Mild increase in intra‑ocular pressure - Temporary conjunctival redness

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, itching) - Persistent mydriasis lasting several days - Acute angle‑closure glaucoma - Severe ocular inflammation or uveitis flare - Systemic anticholinergic effects such as dry mouth or tachycardia

Before prescribing Cyclopentolate, clinicians should evaluate ocular and systemic risk factors. - Intra‑ocular pressure assessment: measure baseline pressure to detect narrow‑angle glaucoma risk. - Contraindicated in known narrow‑angle or acute angle‑closure glaucoma. - Use cautiously in patients with systemic anticholinergic sensitivity (e.g., urinary retention, prostatic hypertrophy). - Avoid concurrent use with miotic agents unless specifically directed. - Pregnancy and breastfeeding: safety not established; weigh potential benefits against unknown risks. - Store at room temperature: keep in original container, protect from light and moisture.

Cyclopentolate may interact with other ocular or systemic agents, altering efficacy or safety.

Major Interactions (Avoid): - Other anticholinergic medications: additive systemic anticholinergic effects. - Miotic agents (e.g., pilocarpine): antagonistic action reducing mydriasis. - Systemic adrenergic drugs that raise intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Topical anesthetics: may increase corneal absorption of cyclopentolate. - Beta‑blocker eye drops: monitor intra‑ocular pressure changes. - Systemic antihistamines: potential enhancement of anticholinergic load.